ReviewStem cells international2016
Cell-Based Therapy for Silicosis.
Review in Stem cells international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.
- Artificial Stone Associated Silicosis: A Systematic Review.International journal of environmental research and public health · 2019Pooled it
- The dynamic landscape of alternative splicing during silicosis progression.Respiratory research · 2026Article
- Article
- Diosgenin ameliorates silica-induced tuberculosis in rats.Animal models and experimental medicine · 2025Article
- BI 1015550 Improves Silica-Induced Silicosis and LPS-Induced Acute Lung Injury in Mice.Molecules (Basel, Switzerland) · 2025Article
- A polymorphism in the FAM13A gene confers protection against tuberculosis in Brazilian workers exposed to silica.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Article
- Integration of apaQTL and eQTL analysis reveals novel SNPs associated with occupational pulmonary fibrosis risk.Archives of toxicology · 2024Article
- Framework for implementing collaborative TB-silicosis activities in India: insights from an expert panel.Archives of public health = Archives belges de sante publique · 2024Article
- Trigonelline hydrochloride attenuates silica-induced pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation.Respiratory research · 2024Article
- High-fat Western diet alters crystalline silica-induced airway epithelium ion transport but not airway smooth muscle reactivity.BMC research notes · 2024Article
- Yangqing Chenfei formula alleviates silica-induced pulmonary inflammation in rats by inhibiting macrophage M1 polarization.Chinese medicine · 2023Article
- From Basic Research to Clinical Practice: Considerations for Treatment Drugs for Silicosis.International journal of molecular sciences · 2023Review
- Development of nintedanib nanosuspension for inhaled treatment of experimental silicosis.Bioengineering & translational medicine · 2023Article
- A mixed-methods study on impact of silicosis on tuberculosis treatment outcomes and need for TB-silicosis collaborative activities in India.Scientific reports · 2023Article
- Apelin Prevents and Alleviates Crystalline Silica-induced Pulmonary Fibrosis via Inhibiting Transforming Growth Factor Beta 1-triggered Fibroblast Activation.International journal of biological sciences · 2023Article
- Functional enhancement strategies to potentiate the therapeutic properties of mesenchymal stromal cells for respiratory diseases.Frontiers in pharmacology · 2023Review
- Respiratory symptoms, spirometric, and radiological status of stone-cutting workers in Bangladesh: A cross-sectional study.Health science reports · 2022Article
- A toxicological profile of silica nanoparticles.Toxicology research · 2022Review
- Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration.Signal transduction and targeted therapy · 2022Article
- Small airway dysfunction in pneumoconiosis: a cross-sectional study.BMC pulmonary medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silicosis is the most common pneumoconiosis globally, with higher prevalence and incidence in developing countries. To date, there is no effective treatment to halt or reverse the disease progression caused by silica-induced lung injury. Significant advances have to be made in order to reduce morbidity and mortality related to silicosis. In this review, we have highlighted the main mechanisms of action that cause lung damage by silica particles and summarized the data concerning the therapeutic promise of cell-based therapy for silicosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.